Profile
Hans Vassgård Eid is currently Chairman at Snøtind AS.
Former positions include Investment Director at Foinco Invest AS from 2002 to 2007, Director at Pharmaq AS from 2012 to 2015, Senior Vice President-Business Development at Storebrand ASA from 1998 to 2001, Chief Executive & Financial Officer at Ultimovacs ASA, and Chief Financial Officer at Zelluna ASA. Education includes an MBA from the Norwegian School of Economics & Business Administration.
Hans Vassgård Eid active positions
| Companies | Position | Start |
|---|---|---|
Snøtind AS | Chairman | - |
Former positions of Hans Vassgård Eid
| Companies | Position | End |
|---|---|---|
Pharmaq AS
Pharmaq AS Pharmaceuticals: MajorHealth Technology Operates as a veterinary pharmaceutical company | Director/Board Member | 2014-12-31 |
Foinco Invest AS
Foinco Invest AS Investment ManagersFinance Acts as an alternative investment manager | Chief Investment Officer | 2006-12-31 |
| STOREBRAND ASA | Corporate Officer/Principal | 2000-12-31 |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Chief Executive Officer | - |
Training of Hans Vassgård Eid
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Storebrand ASA
Storebrand ASA Savings BanksFinance Provides savings, insurance and guaranteed pension services | Finance |
Foinco Invest AS
Foinco Invest AS Investment ManagersFinance Acts as an alternative investment manager | Finance |
Pharmaq AS
Pharmaq AS Pharmaceuticals: MajorHealth Technology Operates as a veterinary pharmaceutical company | Health Technology |
Norwegian School of Economics & Business Administration
Norwegian School of Economics & Business Administration Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Health Technology |
Snøtind AS |
- Stock Market
- Insiders
- Hans Vassgård Eid
















